2023
Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID
Bellone S, Siegel E, Santin A. Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID. Gynecologic Oncology Reports 2023, 50: 101301. PMID: 38029227, PMCID: PMC10654147, DOI: 10.1016/j.gore.2023.101301.Peer-Reviewed Original ResearchGynecologic cancer patientsLong COVIDCancer patientsVitamin DPotent anti-inflammatory activityDihydroxyvitamin D levelsPost-acute sequelaeLong COVID symptomsAnti-inflammatory activityMental health impairmentControl cancer patientsExtrarenal conversionPost-AcuteControl patientsAcute infectionBone healthLC patientsPersistent inflammationD levelsCOVID symptomsImmune cellsPlasmatic levelsNovel biomarkersPatientsAbnormal levels
2022
Recommendations for Preclinical Testing of Treatments Against Alzheimer’s Disease-Related Epileptiform Spikes in Transgenic Rodent Models
Jin N, Babiloni C, Drinkenburg W, Hajós M, Nygaard H, Tanila H. Recommendations for Preclinical Testing of Treatments Against Alzheimer’s Disease-Related Epileptiform Spikes in Transgenic Rodent Models. Journal Of Alzheimer’s Disease 2022, 88: 849-865. PMID: 34092642, DOI: 10.3233/jad-210209.Peer-Reviewed Original ResearchConceptsTransgenic rodent modelsAlzheimer's diseaseRodent modelsPreclinical testingEEG spikesEpileptiform spikesAccelerated disease progressionDisease-modifying drugsRat AD modelClear unmet needSuitable animal modelDiagnosis of epilepsyAD pathologyEpileptiform activityAD patientsDisease progressionMultidisciplinary panelClinical valueDrug interventionAD modelAnimal modelsUnmet needModel rodentsAbnormal levelsDisease
2021
Lower Ventromedial Prefrontal Cortex Glutamate Levels in Patients With Obsessive–Compulsive Disorder
Batistuzzo M, Sottili B, Shavitt R, Lopes A, Cappi C, de Mathis M, Pastorello B, Diniz J, Silva R, Miguel E, Hoexter M, Otaduy M. Lower Ventromedial Prefrontal Cortex Glutamate Levels in Patients With Obsessive–Compulsive Disorder. Frontiers In Psychiatry 2021, 12: 668304. PMID: 34168581, PMCID: PMC8218991, DOI: 10.3389/fpsyt.2021.668304.Peer-Reviewed Original ResearchGamma-aminobutyric acidObsessive-compulsive disorderClinical symptomsHealthy controlsExcitatory/inhibitory imbalancePathophysiology of OCDGlu/Gln ratioH-MRS studiesGray matter fractionGlu/CrCortico-striatal circuitsGlutamate levelsExcitatory neurotransmissionNeurochemical imbalanceInhibitory imbalanceStriatal regionsUnderlying neurochemistryN-acetylaspartatePatientsKey neurotransmitterH-MRSVentromedial prefrontal cortexSecondary analysisAbnormal levelsPrefrontal cortex
2020
Cumulative Effects of Social Stress on Reward-Guided Actions and Prefrontal Cortical Activity
Barthas F, Hu MY, Siniscalchi MJ, Ali F, Mineur YS, Picciotto MR, Kwan AC. Cumulative Effects of Social Stress on Reward-Guided Actions and Prefrontal Cortical Activity. Biological Psychiatry 2020, 88: 541-553. PMID: 32276717, PMCID: PMC7434704, DOI: 10.1016/j.biopsych.2020.02.008.Peer-Reviewed Original ResearchConceptsPrefrontal cortical activityCortical activityIndividual layer 2/3 pyramidal neuronsLayer 2/3 pyramidal neuronsStress exposureDepressive-like phenotypeTwo-photon calcium imagingSocial stressChronic social stressIndividual prefrontal neuronsMedial prefrontal cortexPyramidal neuronsMotor subregionsNeural dysfunctionResilient miceCalcium imagingPrefrontal neuronsAbnormal levelsPrefrontal cortexSocial defeatDistinct neural responsesStress-induced lossGoal-directed actionsEnsemble activityDefeat sessions
2018
Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns
Effendi M, Stutsky M, Curran C, Owusu K, Lee A. Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns. Blood 2018, 132: 2284. DOI: 10.1182/blood-2018-99-119379.Peer-Reviewed Original ResearchLow molecular weight heparinAnti-Xa levelsAnti-Xa level monitoringRetrospective chart reviewNon-therapeutic levelsEnoxaparin doseAdult patientsChart reviewCommon indicationDose adjustmentNursing staffBody weightDrug monitoringTherapeutic monitoringAbnormal levelsStudy periodExtreme body weightRoutine laboratory monitoringRenal replacement therapyCertain patient populationsMolecular weight heparinFavorable pharmacokinetic profileRisk of toxicityClinical decision makingEnoxaparin therapy
2017
APOE genotype and early &bgr;-amyloid accumulation in older adults without dementia
Lim Y, Mormino E, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Carroll M, Leon S, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, McAdams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Graff-Radford, MBBCH N, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha D, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. APOE genotype and early &bgr;-amyloid accumulation in older adults without dementia. Neurology 2017, 89: 1028-1034. PMID: 28794245, PMCID: PMC5589795, DOI: 10.1212/wnl.0000000000004336.Peer-Reviewed Original ResearchConceptsLongitudinal Aβ accumulationAβ accumulationAβ groupOlder ageOlder adultsPrimary prevention trialsΒ-amyloid accumulationInfluence of agePrevention trialsAmyloid accumulationΕ4 carriageFlorbetapir PETΕ4 alleleHigh riskChronologic ageLongitudinal accumulationAbnormal levelsLongitudinal rateDementiaLinear mixed modelsAgeHigh rateΕ4AβAdults
2010
Appetite-regulating hormones cortisol and peptide YY are associated with disordered eating psychopathology, independent of body mass index
Lawson EA, Eddy KT, Donoho D, Misra M, Miller KK, Meenaghan E, Lydecker J, Herzog D, Klibanski A. Appetite-regulating hormones cortisol and peptide YY are associated with disordered eating psychopathology, independent of body mass index. European Journal Of Endocrinology 2010, 164: 253-261. PMID: 21098684, PMCID: PMC3677777, DOI: 10.1530/eje-10-0523.Peer-Reviewed Original ResearchConceptsBody mass indexHypothalamic amenorrheaAnorexia nervosaGhrelin levelsEating Disorder Examination QuestionnaireMass indexEating Disorder Inventory-2Functional hypothalamic amenorrheaAppetite-regulating hormonesCross-sectional studyAnorexigenic hormonesPYY levelsLeptin levelsAppetite regulationEDI-2 scoresBody fatDisorder Examination QuestionnaireWeight extremesCortisol levelsAbnormal levelsCortisolSerum samplesDisorder Inventory-2Good healthHormone cortisol
1988
Sarcoidosis and the pancreas
McCormick P, O’Donnell M, McGeeney K, FitzGerald O, McCormick D, FitzGerald M. Sarcoidosis and the pancreas. Irish Journal Of Medical Science 1988, 157: 181-183. PMID: 2460419, DOI: 10.1007/bf02949293.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply